Internal Medicine, Infectious Disease · Dallas, TX
NPI
1083669543
Since 2006
Specialty
Internal Medicine, Infectious Disease
Code 207RI0200X
Group practices
2
Medicare group memberships
Hospitals
2
Hospital affiliations
3409 Worth St Suite 710
Dallas, TX, 75246
Phone (214) 823-2533
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.1M
125,778 services
Medicare patients, 2024
645
Average age 73
Drug cost, 2024
$1.9M
1,801 prescriptions
Company payments, 2025
$50K
From 13 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Christopher J Bettacchi was code J0878 (injection, daptomycin, 1 mg), 24,150 times for 11 patients. In total Christopher J Bettacchi billed 125,778 services in 61 codes, and Medicare paid $1.1M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2010-07-21.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0878 Injection, daptomycin, 1 mg | Office | 24,150 | 11 | $0.07 | $1,708 |
| J0875 Injection, dalbavancin, 5 mg | Office | 6,000 | 11 | $11.60 | $70K |
| J0897 Injection, denosumab, 1 mg | Office | 4,021 | 60 | $19.13 | $77K |
| 99232 Hospital E&M - Subsequent | Facility | 1,163 | 339 | $60.74 | $71K |
| 99214 Office E&M - Established | Office | 475 | 190 | $87.39 | $42K |
| 99233 Hospital E&M - Subsequent | Facility | 392 | 125 | $91.33 | $36K |
| 96365 Intravenous Infusion, Hydration | Office | 328 | 75 | $47.49 | $16K |
| 99223 Hospital E&M - Initial | Facility | 258 | 228 | $133.74 | $35K |
| 96372 Injection Administration | Office | 176 | 71 | $8.71 | $1,533 |
| J1335 Injection, ertapenem sodium, 500 mg | Office | 98 | 11 | $8.06 | $790 |
| J3489 Injection, zoledronic acid, 1 mg | Office | 90 | 18 | $4.66 | $420 |
| 96413 Chemotherapy Administration | Office | 77 | 13 | $91.95 | $7,080 |
| 99215 Office E&M - Established | Office | 65 | 47 | $129.27 | $8,402 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 48 | 39 | $12.74 | $611 |
| 36573 Venous Catheter Insertion | Office | 33 | 29 | $294.84 | $9,730 |
By year: 2022 $1.6M for 174,690 services; 2023 $1.8M for 179,923 services; 2024 $1.1M for 125,778 services.
Medicare prescription drug claims, 2024
In 2024, the drug Christopher J Bettacchi prescribed most often to Medicare patients was Daptomycin, with 276 prescriptions and refills. In total Christopher J Bettacchi wrote 1,801 Medicare prescriptions that cost $1.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Daptomycin Generic | 276 | 279 | 82 | $217K |
| Ertapenem Ertapenem Sodium | 248 | 253 | 78 | $126K |
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | 119 | 119 | 12 | $470K |
| Ceftriaxone Ceftriaxone Sodium | 102 | 103 | 39 | $12K |
| Minocycline Hcl Generic | 88 | 116 | 32 | $2,994 |
| Fosfomycin Tromethamine Generic | 87 | 87 | 12 | $24K |
| Triumeq Abacavir/Dolutegravir/Lamivudi | 81 | 81 | Under 11 | $297K |
| Cefepime Hcl Generic | 79 | 80 | 17 | $14K |
| Cephalexin Generic | 43 | 53 | Under 11 | $827 |
| Meropenem Generic | 42 | 42 | 11 | $8,127 |
| Dovato Dolutegravir Sodium/Lamivudine | 40 | 42 | Under 11 | $121K |
| Micafungin Micafungin Sodium | 38 | 38 | Under 11 | $8,920 |
| Ciprofloxacin Hcl Generic | 36 | 38 | 19 | $654 |
| Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav | 34 | 34 | 14 | $796 |
| Prezcobix Darunavir/Cobicistat | 34 | 34 | Under 11 | $80K |
Brand drugs: 524 claims; generic drugs: 1,277 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Christopher J Bettacchi $50K ($50K in general payments such as food, travel and fees) from 13 companies. The largest payer was ViiV Healthcare Company with $47K.
| Company | Payments | Amount |
|---|---|---|
| ViiV Healthcare Company GSK | 96 | $47K |
| Merck Sharp & Dohme LLC MRK | 11 | $1,259 |
| Gilead Sciences, Inc. GILD | 13 | $738 |
| Insmed, Inc. INSM | 7 | $188 |
| Astellas Pharma US Inc 4503.T | 4 | $88.66 |
| Shionogi Inc 4507.T | 5 | $81.09 |
| Abbvie Inc. ABBV | 3 | $77.46 |
| Pfizer Inc. PFE | 3 | $74.45 |
| Paratek Pharmaceuticals, Inc. | 2 | $34.93 |
| Theratechnologies Inc. THTX | 1 | $30.58 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.